SPHRF - COVID-19 Treatments: Remdesivir Disappoints Antiviral SPL7013 And Monoclonal Antibodies Interesting For Prevention/Early-Stage Treatment
Prospects for treating early stage COVID-19 remain uncertain, with a host of monoclonal antibody products and Starpharma’s (OTCQX:SPHRY) nasal SPL7013 antiviral spray vying for a role for prevention of infection and early treatment. Here I update on the latest developments with remdesivir, convalescent plasma, monoclonal antibodies and Starpharma’s SPL7013 antiviral. For investors, the stock to watch is Starpharma as over the last 3 trading days in Australia, the stock price on the ASX has risen almost 50% on good volume. With poor prospects for treatments for late stage COVID disease, and anyone’s guess